![]() ![]() If you are having difficulty accessing this website, please call or email us at 1-85 or so that we can provide you with the services you require through alternative means. NETSPOT is the first and only kit for the. (AAA), a Novartis company, today announced that Health Canada has approved NETSPOT (kit for the preparation of gallium ( 68 Ga) oxodotreotide injection) for the evaluation of neuroendocrine tumours (NETs). Background: Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NETs). ![]() GoodRx works to make its website accessible to all, including those with disabilities. Saint-Genis-Pouilly, France, April7, 2020 Advanced Accelerator Applications S.A. Truven Health does not assume any responsibility or risk for your use of the Truven Health products. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. ![]() Additionally, TRUVEN HEALTH MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. Truven Health and GoodRx make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. These products are provided 'AS IS' and 'as available' for use, without warranties of any kind, either express or implied. As part of a Compassionate Expanded access program, such advanced NET patients progressing under conventional therapy can benefit from this therapy program here at UPMC Presbyterian.The use of the Truven Health products is at your sole risk. In Trial A, 97 adult patients with known or suspected neuroendocrine tumors (NETs) were evaluated. This new imaging tool also allows our oncologists to determine if some of their advanced NET patients could benefit from a new Peptide Receptor Radionuclide Therapy (PRRT) that specifically targets somatostatin receptors in these cancer cells. The efficacy of NETSPOT was established in three open-label, single center trials (Study A-C). After its introduction in our imaging centers at Hillman and Presby, there has been an overwhelming response from our patients and oncologists from within the UPMC system and also from outside the region. NETs are rare noncancerous (benign) or cancerous (malignant) tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. Nearly 90 percent of NETs can be identified with 68Ga-DOTATATE (NETSPOT). A plethora of scientific data have advocated for its use in clinical staging and management of such NETs. A neuroendocrine tumor (NET) occurs when cells of the bodys neuroendocrine. This novel molecular imaging technology Ga-68 DOTATATE ( Netspot ™) had been widely anticipated by our oncologists and patients alike. Ga 68 Netspot PET/CT scan: An imaging procedure that uses a radioactive substance that binds to hormone receptors, highlighting the neuroendocrine tumors on. As part of our long standing commitment and dedication to cancer care, we are very excited to announce that UPMC ( Hillman cancer center and Presbyterian) is the first hospital system in Western Pennsylvania and one of the first 10 centers in the country to offer a new cutting-edge technology for imaging Neuroendocrine tumors (NETs). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |